News for SpringWorks Therapeutics Inc Registered Shs

Seeking Alpha 16d

Madrigal, Ipsen, SpringWorks get EU backing for their drugs

TipRanks 40d

Barclays Remains a Hold on Springworks Therapeutics (SWTX)

GlobeNewswire 44d

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

Seeking Alpha 44d

SpringWorks gets EU endorsement for genetic disorder treatment

TipRanks 44d

SpringWorks Therapeutics receives positive CHMP opinion for mirdametinib

TipRanks 55d

Barclays Sticks to Its Hold Rating for Springworks Therapeutics (SWTX)

Seeking Alpha 63d

Notable healthcare headlines for the week: Gilead, CVS Health, Sanofi in focus

TipRanks 67d

Biotech Alert: Searches spiking for these stocks today

TipRanks 67d

SpringWorks Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

TipRanks 69d

SpringWorks Therapeutics downgraded to Hold from Buy at TD Cowen

TipRanks 69d

SpringWorks Therapeutics downgraded to Neutral from Buy at Guggenheim

TipRanks 69d

Amazon sellers pull away from Prime Day, IBM to invest in U.S.: Morning Buzz

TipRanks 69d

Piper says SpringWorks deal suggests Immunome’s varegacestat ‘undervalued’

TipRanks 69d

SpringWorks Therapeutics downgraded to In Line from Outperform at Evercore ISI

TipRanks 69d

SpringWorks Therapeutics downgraded to Equal Weight from Overweight at Barclays

TipRanks 69d

SpringWorks Therapeutics downgraded to Neutral from Outperform at Wedbush

TipRanks 69d

M&A News: Cancer Fighting BioTech SpringWorks Bought by German Firm Merck for $3.9B.

TipRanks 69d

Merck KGaA to acquire SpringWorks Therapeutics for $47 per share in cash

GlobeNewswire 69d

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

Seeking Alpha 69d

Merck KGaA to buy Springworks for $3.9 billion

TipRanks 70d

SpringWorks expects CHMP of EMA will adopt MAA opinion on nirogacestat in Q2

GlobeNewswire 70d

SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

Seeking Alpha 71d

Key deals this week: Ant Group, Boeing, EQT, Calibre Mining and more

TipRanks 72d

BofA moves to No Rating on SpringWorks Therapeutics

Seeking Alpha 72d

SpringWorks jumps as Merck KGaA reportedly nears $3.5B buyout deal

TipRanks 72d

M&A News: Merck KGaA to Buy SpringWorks for $3.5B to Boost Oncology Business

TipRanks 73d

Merck KGaA confirms late-stage talks to acquire SpringWorks for $47 per share

TipRanks 73d

Merck KGaA near $47 per share deal to buy SpringWorks Therapeutics, WSJ says

TipRanks 75d

SpringWorks EU approval would enhance strategic value, says Evercore

TipRanks 75d

Positive opinion for Ogsiveo would de-risk SpringWorks deal, says Barclays

TipRanks 80d

SpringWorks Therapeutics price target lowered to $84 from $87 at BofA

TipRanks 80d

Springworks Therapeutics (SWTX) Receives a Buy from Bank of America Securities

Seeking Alpha 122d

SpringWorks gains after cancelling from investor conference

TipRanks 122d

Merck KGaA says ‘no certainty’ SpringWorks deal will be signed

TipRanks 122d

SpringWorks cancelled from conference this week, says Barclays

TipRanks 125d

Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR) and Springworks Therapeutics (SWTX)

TipRanks 131d

J.P. Morgan Sticks to Its Buy Rating for Springworks Therapeutics (SWTX)

TipRanks 135d

Wall Street Analysts Are Bullish on Top Healthcare Picks

TipRanks 135d

SpringWorks Therapeutics price target lowered to $77 from $78 at Guggenheim

TipRanks 135d

Wall Street Analysts Are Bullish on Top Healthcare Picks

TipRanks 135d

Wall Street Analysts Are Bullish on Top Healthcare Picks

TipRanks 136d

Analysts Are Bullish on These Healthcare Stocks: Aura Biosciences Inc (AURA), Springworks Therapeutics (SWTX)

Seeking Alpha 136d

SpringWorks Therapeutics jumps after results, conference call cancellation

GlobeNewswire 136d

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

TipRanks 136d

SpringWorks Therapeutics reports FY24 EPS ($3.48), consensus ($3.16)

Seeking Alpha 136d

SpringWorks Therapeutics GAAP EPS of -$3.48 misses by $0.43, revenue of $191.59M beats by $0.74M

TipRanks 137d

SpringWorks, Jennifer Fisher team to increase understanding of desmoid tumors

Seeking Alpha 141d

Key deals this week: Papa John's, Spirit Airlines, Novartis, Banco Santander and more

TipRanks 143d

SpringWorks Therapeutics price target raised to $87 from $65 at BofA

TipRanks 144d

SpringWorks Therapeutics CEO sells $2.56M in common stock

	
		OSZAR »